Christopher Yea - 14 Feb 2024 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Reporting relationship: CHIEF DEVELOPMENT OFFICER
Issuer ticker: KALV
Reported as of: 14 Feb 2024
Net transaction value: -$598,661
SEC form: 4
Accepted by SEC: 16 Feb 2024, 16:18:15 UTC
Prior SEC filing: 13 Feb 2024
Next SEC filing: 21 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact

Key filing fact

Christopher Yea filed Form 4 for KalVista Pharmaceuticals, Inc. (KALV) on 16 Feb 2024.

Key facts

This page summarizes Christopher Yea's Form 4 filing for KalVista Pharmaceuticals, Inc. (KALV).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 Feb 2024, 16:18.

Change

Previous filing in this sequence was filed on 13 Feb 2024.
Current net transaction value: -$598,661.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KALV transaction

Common Stock

Sale

Transaction value: $598,661
Shares: -39,886
Change %: -38%
Price: $15.01
Shares after: 66,160
Date: 14 Feb 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance stock units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.